Analyst firms · Leerink Partners · PRCT

Leerink Partners PRCT price target and rating history

PROCEPT BioRobotics Corporation (PRCT) · Health Care

Leerink Partners rates PROCEPT BioRobotics Corporation (PRCT) Market Perform with a $29 price target, as of its latest action on Jun 11, 2026. It has published 4 rating actions on PRCT since October 2021, including 0 upgrades and 1 downgrade. Across 8 firms with a PRCT price target in the last 12 months, the median target is $27. Leerink Partners's $29 is 7% above that.

Current rating
Market Perform
Price target
$29
Median target, all firms
$27
Actions on PRCT
4

Leerink Partners price target on PRCT

$55$42$2920222023202420252026
Leerink Partners price target on PRCT, each point a stated target, October 2021 to June 2026.

Every Leerink Partners rating on PRCT

How other firms rate PRCT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysOverweight$30Oct 7, 2026
William BlairMkt PerformAug 5, 2026
Wells FargoEqual Weight$19Aug 5, 2026
UBSNeutral$20Jul 28, 2026
Truist SecuritiesHold$25Jul 6, 2026
Evercore ISIOutperform$30Jun 24, 2026
Leerink PartnersMarket Perform$29Jun 11, 2026
Robert W. BairdNeutral$30Mar 6, 2026
OppenheimerPerformFeb 26, 2026
BofA SecuritiesUnderperform$20Feb 26, 2026

Questions about Leerink Partners and PRCT

What is Leerink Partners's price target for PRCT?
Leerink Partners's latest stated price target for PROCEPT BioRobotics Corporation (PRCT) is $29, from its action on Jun 11, 2026.
What is Leerink Partners's rating on PRCT?
Leerink Partners rates PRCT Market Perform, a neutral rating, as of Jun 11, 2026.
When did Leerink Partners last change its view on PRCT?
On Jun 11, 2026, Leerink Partners downgrades to Market Perform from Outperform, price target $29.
How does Leerink Partners's PRCT target compare with other analysts?
Across 8 firms with a PRCT price target in the last 12 months, the median target is $27. Leerink Partners's $29 is 7% above that.

More PRCT rating histories

All Leerink Partners ratingsPRCT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.